Delamanid: Safety and Efficacy Analysis
Туберкулез и болезни лёгких, 2023 The review presents the analysis of 50 publications describing treatment of multiple drug resistant tuberculosis with regimens containing the new drug of delamanid.
G. N. Mozhokina +3 more
doaj +3 more sources
Delamanid Resistance: Update and Clinical Management
Clinical Infectious Diseases, 2020 Abstract Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence.
Jan-Willem Alffenaar +2 more
exaly +7 more sources
Delamanid or Pretomanid? A Solomonic Judgement! [PDF]
Journal of Antimicrobial Chemotherapy, 2022 Abstract Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are urgently needed. The landscape of TB treatment has changed considerably over the last decade with the approval of three new compounds: bedaquiline, delamanid and pretomanid. Of these, delamanid and pretomanid belong to the same class of
Jurriaan E M de Steenwinkel +2 more
exaly +5 more sources
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis [PDF]
New England Journal of Medicine, 2012 Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly
Gee Young Suh +2 more
exaly +5 more sources
The role of delamanid in the treatment of drug-resistant tuberculosis [PDF]
Therapeutics and Clinical Risk Management, 2015 Joseph M Lewis,1 Derek J Sloan2,3 1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK ...
Lewis JM, Sloan DJ
doaj +9 more sources
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis [PDF]
New England Journal of Medicine, 2015 Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
Sébastien Gagneux +2 more
exaly +7 more sources
Profile of delamanid for the treatment of multidrug-resistant tuberculosis
Drug Design, Development and Therapy, 2015 John D Szumowski,1,2 John B Lynch11Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; 2Division of AIDS Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA Abstract: New approaches
Szumowski JD, Lynch JB
doaj +6 more sources
Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study [PDF]
Frontiers in MedicineBackgroundSingle center preliminary results from a multicenter, prospective, observational study whose aims were to investigate the efficacy and safety of 24-week delamanid-containing regimens in Chinese multidrug-resistant/rifampicin-resistant ...
Fuping Yang +6 more
doaj +2 more sources
Implications of edge cases for antimicrobial susceptibility predictions for rifampin, delamanid, and pretomanid with the WHO Mycobacterium tuberculosis mutation catalog [PDF]
Microbiology SpectrumThe WHO mutation catalog is the reference for genotypic antimicrobial susceptibility predictions (ASPs) for Mycobacterium tuberculosis. To increase sensitivity, WHO endorsed additional grading rules to classify mutations with insufficient experimental ...
Noud Hermans +24 more
doaj +2 more sources
A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial [PDF]
Signal Transduction and Targeted TherapyTuberculosis (TB) is a contagious disease that threatens human health worldwide. Combination chemotherapy is usually recommended for this disease. Recently, 2 nitroimidazole-based agents, namely, delamanid and pretomanid, have been approved by regulatory
Naihui Chu +15 more
doaj +2 more sources